Cover Image
市場調查報告書

癌症幹細胞治療市場預測

Cancer Stem Cell Therapies Market, 2017-2030

出版商 ROOTS ANALYSIS 商品編碼 597641
出版日期 內容資訊 英文 270 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症幹細胞治療市場預測 Cancer Stem Cell Therapies Market, 2017-2030
出版日期: 2017年12月06日 內容資訊: 英文 270 Pages
簡介

本報告提供癌症幹細胞治療的市場調查,癌症幹細胞與癌症幹細胞治療概要,臨床開發趨勢,已上市藥物及開發後期藥物的詳細內容簡介,第二階段分子藥的簡介,適應症、治療標的、分子類型等各種區分的市場成長預測,各藥物的市場成長預測等彙整資料。

第1章 序章

第2章 摘要整理

第3章 簡介

  • 癌症概要
  • 癌症起源的追蹤
  • 癌症幹細胞為目標的治療策略
  • 未來展望

第4章 競爭環境

  • 本章概要
  • 癌症幹細胞治療:開發平台

第5章 主要考察

  • 本章概要
  • 臨床開發分析:潛在的標的途徑
  • 臨床開發分析:潛在的分子標的
  • 臨床開發分析:各治療領域、分子類型、開發階段
  • 產品的競爭力分析

第6章 在社群媒體上的新興趨勢

第7章 出版物分析

第8章 已上市藥物、開發後期的藥物:詳細內容簡介

  • 本章概要
  • Erivedge® / Vismodegib / GDC-0449 (Roche)
  • Odomzo® / Sonidegib / LDE225 (Novartis)
  • BL-8040 (BioLineRx)
  • Imetelstat / GRN163L (Geron Corporation)
  • Napabucasin / BB-608 (Boston Biomedical)
  • Rovalpituzumab Tesirine / Rova-T (AbbVie)
    • 產品概要
    • 作用機制
    • 目前開發情形
    • 主要的臨床實驗結果
    • 開發經營者概要

第9章 第二階段分子:簡介

  • 本章概要
  • Amcasertib / BBI-503 (Boston Biomedical)
  • AZD9150 / ISIS-STAT3-2.5Rx (Ionis Pharmaceuticals / AstraZeneca)
  • BHQ 880 (MorphoSys / Novartis)
  • CRLX 101 (Bluelink Pharma)
  • CX-02 (Cantex Pharmaceuticals)
  • Glasdegib / PF-04449913 (Pfizer)
  • GLG-801 (Genus Oncology)
  • GO-203 (GLG Pharma)
  • ibrutinib (Janssen)
  • MDNA55 (Medicenna Therapeutics)
  • ONC201 (Oncoceutics)
  • Patidegib / IPI-926 / Saridegib (PellePharm)
  • PT2385 (Peloton Therapeutics)
  • Reparixin (Dompé Farmaceutici)
  • Sulforadex / SFX-01 (Evgen Pharma)
  • SUBA-Itraconazole (HedgePath Pharmaceuticals)
  • VicOryx (ORYX)

第10章 市場預測、市場機會分析

  • 本章概要
  • 調查範圍、規定
  • 預測手法
  • 整體市場預測
    • 明細:各適應症
    • 明細:各治療標的
    • 明細:各分子類型
    • 產品佔有率
  • 癌症幹細胞治療市場:各藥物預測
    • Erivedge®
    • Odomzo®
    • Napabucasin
    • BL-8040
    • Rova-T
    • Imetelstat
    • BHQ 880
    • CRLX101
    • Glasdegib / PF-04449913
    • Amcasertib / BBI503
    • CX-02
    • GLG-801
    • MDNA55
    • ONC201
    • Patidegib / IPI-926 / Saridegib
    • Reparixin
    • SUBA-Itraconazole
    • VicOryx
    • Sulforadex / SFX-01
    • Ibrutinib
    • PT2385
    • GO-203
    • AZD9150 / ISIS-STAT3-2.5Rx

第11章 總論

第12章 採訪記錄

第13章 附錄1:圖表資料

第14章 附錄2:企業、團體清單

目錄
Product Code: RA10096

Cancer stem cells (CSCs) are known to be rare, immortal cells within a tumor that can both self-renew and differentiate into several cell types that form the tumor mass. Over time, the development of CSCs has been shown to be associated with several signaling pathways, which regulate the survival and proliferation of these cells. Presently, a number of initiatives are underway to explore specific targets that can be used to selectively eliminate cancer stem cells and, thereby, confer therapeutic benefits to patients suffering from various forms of cancers. The presence of CSCs has been established in various cancers, including oesophageal cancer, gastric cancer, intestinal cancer, colon cancer, hepatic cancer and pancreatic cancer. However, it is postulated that these self-renewing CSCs represent only a small fraction of the cell population (approximately 1%) within the bulk tumor mass. The frequent failure in trying to treat advanced cancers using the current standard of care therapies has been attributed to the presence of CSCs as these cells actively resist all methods of treatment, including chemotherapy and radiotherapy.

The objective of the ongoing R&D is to develop novel CSC directed treatments that can combat complications, such as off target toxicities and disease relapse, associated with the current standard of care treatments. In fact, between January 2008 and December 2016, the number of publications in this domain grew at an annualized rate of 10.4%; overall, there are over 9000 publications available on PubMed, indicating the extensive research activity unfolding in this domain.

Synopsis:

The ‘Cancer Stem Cell Therapies Market, 2017-2030' report examines the current landscape and the future outlook of the growing pipeline of products targeting CSCs. We identified over 150 molecules that are currently being investigated as therapeutic interventions for the elimination of CSCs. Over the past few years, this burgeoning field of research has captured the interest of several players in the pharmaceutical industry. Amongst other elements, the report features:

  • An elaborate discussion on the origin, properties and methods for identification of CSCs. It covers the key therapeutic strategies that are being investigated for eliminating CSCs; these include targeting signaling pathways, targeting cancer stemness factors and related surface markers, inhibiting ATP-binding cassette transporters, targeting the tumor microenvironment, and the induction of apoptosis in CSCs.
  • A review of the overall landscape of the CSC therapy market with respect to the phase of development, key therapeutic targets, oncological indications, mode of administration, type of molecule (small molecule, monoclonal antibody, peptides, bispecific antibody, gene therapy, fusion proteins and other biologics), geographical distribution of R&D efforts and the key players in this domain.
  • A detailed publication analysis on more than 340 articles that have been published between September 2016 and October 2017, highlighting the key focus areas of the ongoing research activity in this field.
  • Comprehensive profiles of phase III and marketed drugs featuring a brief company overview and financial details, product description, mechanism of action, current status of development, active clinical trials, key clinical trial results, manufacturing information, dosage and sales information, collaborations established related to the product, and a comprehensive future outlook of the developer. Additionally, the report also includes profiles of drugs that are in phase II of clinical development.
  • Insightful representations of the distribution of CSC targeting molecules across various parameters, such as target molecular pathway, therapeutic area, type of molecule and highest phase of development. The report features a bull's eye analysis to specifically highlight the most popular targets from a clinical standpoint. In addition, we have provided a comprehensive overview (in the form of a 2 X 2 matrix) of the competitive landscape of developers, highlighting each developer's product portfolio, company size and location of headquarters.
  • An analysis depicting the prevalent and emerging trends related to CSC therapies as observed on the social media platform, Twitter. In addition to the yearly trend, the analysis highlights the most talked about therapeutic targets for CSC therapies and the popular cancer indications.

One of the key objectives of the report was to estimate the future size of the CSC therapy market, specifically in the US and EU. We adopted a bottom-up approach to evaluate the likely success and growth of marketed drugs and those that are in phase II and phase III of clinical development, over the next 10-15 years. The insights generated on the future opportunity are segmented on the basis of key indications, important target strategies and key products. In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the period 2017-2030, namely the conservative, base and optimistic scenarios, which represent three different tracks of the industry's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The report presents details of conversations with (in alphabetical order of company name) Stephen Franklin (CEO, Evgen Pharma), Steven Swanson (Senior Vice President, ImmunoCellular Therapeutics) and Jaffer Ajani (Researcher at MD Anderson Cancer Center).

Example Highlights:

  • 1. Around 150 product candidates are currently under various stages of development for a diverse range of indications. Two molecules, namely Erivedge® (Roche) and Odomzo® (Novartis), are commercially available. Nearly 49% of the pipeline molecules are under clinical development; of these, 4 molecules are being investigated in phase III, 18 molecules in phase II, 18 molecules in phase I/II and 35 molecules in phase I clinical trials. Majority (50%) of the product candidates in the pipeline are still in the preclinical and discovery stages.
  • 2. A significant proportion (49%) of product candidates in the pipeline target various CSC signaling pathways. Specifically, the two commercially available drugs are designed to target the hedgehog pathway. Of the four important pathways (BMI1, Hedgehog, Notch, Wnt), the Wnt pathway (specifically the β-catenin protein) is presently considered to be the most important target; 25% of the pipeline candidates are being developed to eliminate CSCs by modulating this particular signaling cascade.
  • 3. 71% of the products in the development pipeline are designed to treat solid tumors, including basal cell carcinoma, breast cancer, colon cancer, ovarian cancer and prostate cancer. Nearly 18% of the molecules are being developed for the treatment of hematological malignancies, such as acute myeloid leukemia, acute lymphocytic leukemia, multiple myeloma and myelodysplastic syndrome. The remaining 11% of the pipeline molecules are being developed for treating both types of cancers.
  • 4. The market landscape is characterized by the presence of large-sized (19), mid-sized (19) and small-sized companies (67). Some of the prominent large-sized companies engaged in this domain include (in alphabetical order) AbbVie, AstraZeneca, Bristol Myers Squibb, Dompé Farmaceutici, Janssen, Merck, MorphoSys, Novartis, Pfizer, Roche / Genentech and Sanofi. Similarly, mid-sized companies that are actively contributing to the development of CSC therapies include (in alphabetical order) ASINEX, Boston Biomedical, OncoMed Pharmaceuticals, Redx Pharma and Taiwan Liposome Company. In addition, small companies, such as (in alphabetical order) Agilvax, amcure, BioLineRx, CellCentric, Celon Pharma, Evgen Pharma, Geron, Genus Oncology, HedgePath Pharmaceuticals, ImmunoCellular Therapeutics, Medicenna Therapeutics, Oncoceutics, PellePharm, Peloton Therapeutics, SATHGEN BIOTECH, Verastem and WntResearch are also actively involved in this domain.
  • 5. Several universities / research organizations have also made significant contributions to the development efforts in this market. Examples include (in alphabetical order) the Centre Léon-Bérard, Dana-Farber Cancer Institute, inVentiv Health Clinical, Maastricht University Medical Center, Duke University Medical Center, The Royal Marsden NHS Foundation Trust and University of Pittsburgh.
  • 6. With many candidates in the late stages of development, the market is likely to witness several approvals over the coming decade. We expect the market to grow at an annualized rate of ~33% till 2030. In fact, specific products, being developed for indications with very large target patient populations, are anticipated to achieve blockbuster status (sales over USD 1 billion) and become prime contributors to future revenues.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 presents an executive summary of the report. It offers a high-level view on where the CSC therapy market is headed in the long term.

Chapter 3 provides a general introduction to the underlying concepts of CSC. In this section, we have briefly discussed the origin, properties, and techniques for identification and isolation of CSCs. The chapter covers details on the fundamentals of the various therapeutic strategies that are being designed against CSCs. These include signaling pathways such as the WNT pathway, Notch pathway, Hedgehog pathway, BMI-1 pathway, important regulatory factors that govern stemness in cancer cells, elements influencing the tumor microenvironment and important surface markers. In addition, the chapter highlights the challenges and future prospects associated with development of CSC therapeutics.

Chapter 4 provides a comprehensive overview of the current landscape of CSC therapeutics market. It includes information on potential drug candidates that are currently in different stages of development (both clinical and preclinical / discovery). It presents a detailed analysis of the pipeline of products in this domain, including information on the current phases of development, most common indications, target strategies, type of molecule, popular routes of administration, geographical distribution of the companies involved in this space. We have also highlighted the key players active in this domain.

Chapter 5 presents important insights from the current pipeline. The chapter features a detailed funnel analysis, highlighting the distribution of candidate drugs based on their target pathways, and highest phase of development. It also highlights the most popular targets within each therapeutic strategy. In addition, it features a competitive landscape of developers, along with information on each developer's product portfolio, company size and the location of headquarters. In addition, this section features a bull's eye analysis of the molecules that are in the clinical stage, highlighting the type of molecule and the highest phase of development.

Chapter 6 provides insights on the popularity of CSC therapieson the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2017, and the most significant events responsible for increase / decrease in the volume of tweets each year. Additionally, the chapter showcases the most talked about therapeutic targets and the important indications, as observed on social media.

Chapter 7 provides a comprehensive publication analysis, highlighting the recent trends in published literature related to CSC therapies. The chapter provides details on novel methods, as well as the attempts that are being made to add value to the ongoing efforts within this domain.

Chapter 8 provides detailed profiles of the molecules that are either marketed, or in phase III of clinical development. Each profile provides information on the mechanism of action, current status of development, dosage form and treatment regimen, information on clinical studies and key clinical trial results of the drug. It also includes an overview of the developer, its financial details and an informed future outlook.

Chapter 9 presents brief profiles of the molecules that are in phase II of clinical development. Each profile provides information on the developer, mechanism of action of the molecule, route of administration, current status of development, clinical studies, key clinical trial results, recent collaborations, and drug-specific designations (if any).

Chapter 10 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of CSC therapeutics that are either marketed or are in advanced stages of clinical development (phase II and phase III). The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of the key indications, important therapeutic strategies and the important players in the market.

Chapter 11 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of company name) Stephen Franklin (CEO, Evgen Pharma), Steven Swanson (Senior Vice President, ImmunoCellular Therapeutics) and Jaffer Ajani (Researcher at MD Anderson Cancer Center).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. An Overview of Cancer
  • 3.2. Tracing the Origins of Cancer
    • 3.2.1. Origin of Cancer Stem Cells
      • 3.2.1.1. Stem Cell Mutations
      • 3.2.1.2. Adult Stem Cells
      • 3.2.1.3. De-differentiation
    • 3.2.2. Properties of Cancer Stem Cells
      • 3.2.2.1. Self-renewal, Proliferation and Differentiation
      • 3.2.2.2. Dysregulation of Molecular Signaling Pathways
      • 3.2.2.3. Presence of Specific Surface Markers
      • 3.2.2.4. Expression of Efflux Transporter
    • 3.2.3. Identification of Cancer Stem Cells
  • 3.3. Therapeutic Strategies for Targeting Cancer Stem Cells
    • 3.3.1. Targeting Cancer Stem Cell Signaling Pathways
      • 3.3.1.1. Hedgehog Signaling Pathway
      • 3.3.1.2. Notch Signaling Pathway
      • 3.3.1.3. Wnt Signaling Pathway
      • 3.3.1.4. BMI1 Signaling Pathway
      • 3.3.1.5. Cross-Talk Between Signaling Pathways
    • 3.3.2. Targeting Cancer Stemness Factors
      • 3.3.2.1. Nanog
      • 3.3.2.2. Sox-2
      • 3.3.2.3. Oct-4
      • 3.3.2.4. Myc
      • 3.3.2.5. Klf-4
    • 3.3.3. Silencing Oncogenes
    • 3.3.4. Targeting Cancer Stem Cell Surface Markers
    • 3.3.5. Inhibiting ATP-Binding Cassette Transporters
    • 3.3.6. Targeting the Tumor Microenvironment
    • 3.3.7. Regulating Epigenetic Changes
    • 3.3.8. Induction of Apoptosis in Cancer Stem Cells
    • 3.3.9. Induction of Differentiation in Cancer Stem Cells
  • 3.4. Future Perspectives

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Cancer Stem Cell Therapies: Development Pipeline
    • 4.2.1. Distribution by Phase of Development
    • 4.2.2. Distribution by Therapeutic Area
    • 4.2.3. Distribution by Therapeutic Strategies
    • 4.2.4. Distribution by Type of Molecule
    • 4.2.5. Distribution by Route of Administration
    • 4.2.6. Distribution by Geography of Developer
    • 4.2.7. Most Active Industry Players

5. KEY INSIGHTS

  • 5.1. Chapter Overview
  • 5.2. Cancer Stem Cell Therapies: Clinical Development Analysis of Potential Target Pathways
  • 5.3. Cancer Stem Cells Therapies: Clinical Development Analysis of Potential Molecular Targets
  • 5.4. Cancer Stem Cell Therapies: Clinical Development Analysis based on Therapeutic Area, Type of Molecule and Phase of Development
  • 5.5. Cancer Stem Cell Therapies: Product Competitiveness Analysis based on Developer Landscape

6. EMERGING TRENDS ON SOCIAL MEDIA

  • 6.1. Chapter Overview
  • 6.2 Cancer Stem Cells: Trends on Twitter
    • 6.2.1. Year-wise Activity Analysis (2012-2017)
    • 6.2.2. Popular Therapeutic Targets on Twitter
    • 6.2.3. Popular Indications on Twitter

7. PUBLICATION ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Cancer Stem Cells: Publications Analysis
    • 7.2.1. Analysis by Key Journals
    • 7.2.2. Analysis by Most Popular Targets

8. MARKETED AND LATE-STAGE DRUGS: DETAILED PROFILES

  • 8.1. Chapter Overview
  • 8.2. Erivedge® / Vismodegib / GDC-0449 (Roche)
    • 8.2.1. Product Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Current Status of Development
    • 8.2.4. Key Clinical Trial Results
      • 8.2.4.1. Basal Cell Carcinoma
    • 8.2.5. Dosage, Sales and Manufacturing
    • 8.2.6. Developer Overview
      • 8.2.6.1. Financial Performance
      • 8.2.6.2. Collaborations
      • 8.2.6.3. Future Outlook
  • 8.3. Odomzo® / Sonidegib / LDE225 (Novartis)
    • 8.3.1. Product Description
    • 8.3.2. Mechanism of Action
    • 8.3.3. Current Status of development
    • 8.3.4. Key Clinical Trial Results
      • 8.3.4.1. Basal Cell Carcinoma
      • 8.3.4.2. Myelofibrosis
    • 8.3.5. Dosage, Sales and Manufacturing
    • 8.3.6. Developer Overview
      • 8.3.6.1. Financial Performance
      • 8.3.6.2. Future Outlook
  • 8.4. BL-8040 (BioLineRx)
    • 8.4.1. Product Description
    • 8.4.2. Mechanism of Action
    • 8.4.3. Current Status of Development
    • 8.4.4. Key Clinical Trial Results
      • 8.4.4.1. Acute Myeloid Leukemia
    • 8.4.5. Developer Overview
      • 8.4.5.1. Financial Performance
      • 8.4.5.2. Collaborations
      • 8.4.5.3. Future Outlook
  • 8.5. Imetelstat / GRN163L (Geron Corporation)
    • 8.5.1. Product Description
    • 8.5.2. Mechanism of Action
    • 8.5.3. Current Status of Development
    • 8.5.4. Key Clinical Trial Results
      • 8.5.4.1. Myelodysplastic Syndromes
      • 8.5.4.2. Myelofibrosis
      • 8.5.4.3. Essential Thrombocythemia
    • 8.5.5. Developer Overview
      • 8.5.5.1. Financial Performance
      • 8.5.5.2. Collaborations
      • 8.5.5.3. Future Outlook
  • 8.6. Napabucasin / BB-608 (Boston Biomedical)
    • 8.6.1. Product Description
    • 8.6.2. Mechanism of Action
    • 8.6.3. Current Status of Development
    • 8.6.4. Key Clinical Trial results
      • 8.6.4.1. Gastric Cancer / Gastroesophageal Junction Carcinoma
      • 8.6.4.2. Pancreatic Cancer
      • 8.6.4.3. Colorectal Cancer
      • 8.6.4.4. Metastatic Breast Cancer
      • 8.6.4.5. Advanced Melanoma
      • 8.6.4.6. Non-Small Cell Lung Cancer
    • 8.6.5. Developer Overview
      • 8.6.5.1. Financial Performance
      • 8.6.5.2. Future Outlook
  • 8.7. Rovalpituzumab Tesirine / Rova-T (AbbVie)
    • 8.7.1. Product Description
    • 8.7.2. Mechanism of Action
    • 8.7.3. Current Status of Development
    • 8.7.4. Key Clinical Trial Results
      • 8.7.4.1. Small Cell Lung Cancer
    • 8.7.5. Developer Overview
      • 8.7.5.1. Financial Performance
      • 8.7.5.2. Collaborations
  • 8.7.5.3. Future Outlook

9. PHASE II MOLECULES: TABULATED PROFILES

  • 9.1. Chapter Overview
  • 9.2. Amcasertib / BBI-503 (Boston Biomedical)
  • 9.3. AZD9150 / ISIS-STAT3-2.5Rx (Ionis Pharmaceuticals / AstraZeneca)
  • 9.4. BHQ 880 (MorphoSys / Novartis)
  • 9.5. CRLX 101 (Bluelink Pharma)
  • 9.6. CX-02 (Cantex Pharmaceuticals)
  • 9.7. Glasdegib / PF-04449913 (Pfizer)
  • 9.8. GLG-801 (Genus Oncology)
  • 9.9. GO-203 (GLG Pharma)
  • 9.10. Ibrutinib (Janssen)
  • 9.11. MDNA55 (Medicenna Therapeutics)
  • 9.12. ONC201 (Oncoceutics)
  • 9.13. Patidegib / IPI-926 / Saridegib (PellePharm)
  • 9.14. PT2385 (Peloton Therapeutics)
  • 9.15. Reparixin (Dompé Farmaceutici)
  • 9.16. Sulforadex / SFX-01 (Evgen Pharma)
  • 9.17. SUBA-Itraconazole (HedgePath Pharmaceuticals)
  • 9.18. VicOryx (ORYX)

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Limitations
  • 10.3. Forecast Methodology
  • 10.4. Overall Cancer Stem Cell Therapies Market, 2017-2030
    • 10.4.1. Cancer Stem Cell Therapies Market: Distribution by Indication
    • 10.4.2. Cancer Stem Cell Therapies Market: Distribution by Therapeutic Target
    • 10.4.3. Cancer Stem Cell Therapies Market: Distribution by Type of Molecule
    • 10.4.4. Cancer Stem Cell Therapies Market: Share of Products
  • 10.5. Cancer Stem Cell Therapies Market: Individual Drug Forecasts
    • 10.5.1. Erivedge®
      • 10.5.1.1. Target Patient Population
      • 10.5.1.2. Sales Forecast
    • 10.5.2. Odomzo®
      • 10.5.2.1. Target Patient Population
      • 10.5.2.2. Sales Forecast
    • 10.5.3. Napabucasin
      • 10.5.3.1. Target Patient Population
      • 10.5.3.2. Sales Forecast
    • 10.5.4. BL-8040
      • 10.5.4.1. Target Patient Population
      • 10.5.4.2. Sales Forecast
    • 10.5.5. Rova-T
      • 10.5.5.1. Target Patient Population
      • 10.5.5.2. Sales Forecast
    • 10.5.6. Imetelstat
      • 10.5.6.1. Target Patient Population
      • 10.5.6.2. Sales Forecast
    • 10.5.7. BHQ 880
      • 10.5.7.1. Target Patient Population
      • 10.5.7.2. Sales Forecast
    • 10.5.8. CRLX101
      • 10.5.8.1. Target Patient Population
      • 10.5.8.2. Sales Forecast
    • 10.5.9. Glasdegib / PF-04449913
      • 10.5.9.1. Target Patient Population
      • 10.5.9.2. Sales Forecast
    • 10.5.10. Amcasertib / BBI503
      • 10.5.10.1. Target Patient Population
      • 10.5.10.2. Sales Forecast
    • 10.5.11. CX-02
      • 10.5.11.1. Target Patient Population
      • 10.5.11.2. Sales Forecast
    • 10.5.12. GLG-801
      • 10.5.12.1. Target Patient Population
      • 10.5.12.2. Sales Forecast
    • 10.5.13. MDNA55
      • 10.5.13.1. Target Patient Population
      • 10.5.13.2. Sales Forecast
    • 10.5.14. ONC201
      • 10.5.14.1. Target Patient Population
      • 10.5.14.2. Sales Forecast
    • 10.5.15. Patidegib / IPI-926 / Saridegib
      • 10.5.15.1. Target Patient Population
      • 10.5.15.2. Sales Forecast
    • 10.5.16. Reparixin
      • 10.5.16.1. Target Patient Population
      • 10.5.16.2. Sales Forecast
    • 10.5.17. SUBA-Itraconazole
      • 10.5.17.1. Target Patient Population
      • 10.5.17.2. Sales Forecast
    • 10.5.18. VicOryx
      • 10.5.18.1. Target Patient Population
      • 10.5.18.2. Sales Forecast
    • 10.5.19. Sulforadex / SFX-01
      • 10.5.19.1. Target Patient Population
      • 10.5.19.2. Sales Forecast
    • 10.5.20. Ibrutinib
      • 10.5.20.1. Target Patient Population
      • 10.5.20.2. Sales Forecast
    • 10.5.21. PT2385
      • 10.5.21.1. Target Patient Population
      • 10.5.21.2. Sales Forecast
    • 10.5.22. GO-203
      • 10.5.22.1. Target Patient Population
      • 10.5.22.2. Sales Forecast
    • 10.5.23. AZD9150 / ISIS-STAT3-2.5Rx
      • 10.5.23.1. Target Patient Population
      • 10.5.23.2. Sales Forecast

11. CONCLUSION

  • 11.1. Extensive Research is being Carried out to Harness the Therapeutic Potential Related to Targeting Cancer Stem Cells
  • 11.2. Such Targeted Therapies have Garnered the Interest of both Industry and Non-Industry Players
  • 11.3. With Two Marketed Products and Several Molecules in the Clinical / Preclinical Stages, the Pipeline Appears to be Promising
  • 11.4. Majority of Drugs / Therapies are being Developed to Target Cancer Stem Cell Signaling Pathways
  • 11.5. The Field has Witnessed the Establishment of Several Partnerships and Received Significant Support from Venture Capital Investors
  • 11.6. With Promising Clinical Results, These Therapies are Poised to Achieve Accelerated Growth in the Foreseen Future

12. INTERVIEW TRANSCRIPTS

  • 12.1. Chapter Overview
  • 12.2. Stephen Franklin, CEO, Evgen Pharma
  • 12.3. Steven Swanson, Senior Vice President, Research, ImmunoCellular Therapeutics
  • 12.4. Jaffer Ajani, Researcher, MD Anderson Cancer Centre

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Global Cancer Incidence in 2016: Distribution by Type of Cancer
  • Figure 3.2: Comparison of Conventional Cancer Therapies with CSC Specific Therapy
  • Figure 3.3: Cancer Stem Cell Generation
  • Figure 3.4: Properties of Cancer Stem Cells
  • Figure 3.5 Molecular Pathways Influencing Cancer Stem Cell Renewal
  • Figure 3.6: Hedgehog Pathway: Signaling Cascade
  • Figure 3.7: Notch Signaling Pathway Inhibitors: Key Mechanisms of Action
  • Figure 3.8: Wnt Pathway: Signaling Cascade
  • Figure 3.9: BMI1 Signaling Cascade
  • Figure 3.10: Key Epigenetic Mechanisms
  • Figure 3.11: Apoptosis: Extrinsic and Intrinsic Pathways
  • Figure 4.1: Cancer Stem Cells: List of Related Targets
  • Figure 4.2: Cancer Stem Cell Therapies: Distribution by Phase of Development
  • Figure 4.3: Cancer Stem Cell Therapies: Distribution by Therapeutic Area
  • Figure 4.4: Cancer Stem Cell Therapies: Distribution by Therapeutic Strategies
  • Figure 4.5: Cancer Stem Cell Therapies: Distribution by Target Strategies and Phase of Development
  • Figure 4.6: Cancer Stem Cell Therapies: Distribution by Type of Molecule
  • Figure 4.7: Cancer Stem Cell Therapies: Distribution by Route of Administration
  • Figure 4.8: Cancer Stem Cell Therapies: Distribution by Geography of Developer
  • Figure 4.9: Cancer Stem Cell Therapies: Regional Landscape
  • Figure 4.10: Cancer Stem Cell Therapies: Most Active Industry Players
  • Figure 5.1: Cancer Stem Cell Therapies: Clinical Development Analysis of Potential Target Pathways
  • Figure 5.2: Cancer Stem Cells Therapies: Clinical Development Analysis of Potential Molecular Targets
  • Figure 5.3: Cancer Stem Cell Therapies: Clinical Development Analysis based on Therapeutic Area, Type of Molecule and Phase of Development
  • Figure 5.4: Cancer Stem Cell Therapies: Product Competitiveness Analysis based on Developer Landscape
  • Figure 6.1: Cancer Stem Cells: Trends on Twitter (2012-2017)
  • Figure 6.2: Cancer Stem Cells: Year-wise Trend by Number of Tweets (2012-2017)
  • Figure 6.3: Cancer Stem Cells: Popular Therapeutic Targets on Twitter
  • Figure 6.4: Cancer Stem Cells: Popular Indications on Twitter
  • Figure 7.1: Cancer Stem Cells: Year-Wise Trend of Number of Publications (2008-2016)
  • Figure 7.2: Cancer Stem Cells Publication Analysis: Key Journals
  • Figure 7.3: Cancer Stem Cells Publication Analysis: Most Popular Therapeutic Targets
  • Figure 8.1: Erivedge®: Annual Revenues, 2013-2016 (CHF Million)
  • Figure 8.2: Roche: Annual Revenues, 2012-H1 2017 (CHF Billion)
  • Figure 8.3: Novartis: Annual Revenues, 2011-H1 2017 (USD Billion)
  • Figure 8.4: Geron: Annual Revenues, 2012-H1 2017 (USD Million)
  • Figure 8.5: Sumitomo Dainippon Pharma: Annual Revenues, 2012-2016 (JPY Billion)
  • Figure 8.6: AbbVie: Annual Revenues, 2012-H1 2017 (USD Billion)
  • Figure 10.1: Overall Cancer Stem Cell Therapies Market (Till 2030): Base Scenario (USD Billion)
  • Figure 10.2: Cancer Stem Cell Therapies Market: Distribution by Indication, 2017, 2030 (USD Billion)
  • Figure 10.3: Cancer Stem Cell Therapies Market: Distribution by Molecular Target, 2017, 2030 (USD Billion)
  • Figure 10.4: Cancer Stem Cell Therapies Market: Distribution by Type of Molecule, 2017, 2030 (USD Billion)
  • Figure 10.5: Cancer Stem Cell Therapies Market: Leading Drug Candidates, 2017, 2024, 2030 (USD Billion)
  • Figure 10.6: Erivedge Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.7: Odomzo Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.8: Napabucasin Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.9: BL-8040 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.10: Rova-T Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.11: Imetelstat Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.12: BHQ 880 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.13: CRLX101 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.14: Glasdegib Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.15: Amcasertib Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.16: CX-02 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.17: GLG-801 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.18: MDNA55 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.19: ONC201 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.20: Patidegib Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.21: Reparixin Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.22: SUBA-Itraconazole Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.23: VicOryx Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.24: SFX-01 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.25: Ibrutinib Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.26: PT2385 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.27: GO-203 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.28: AZD9150 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 11.1: Overall Cancer Stem Cell Therapies Market (USD Billion): 2017, 2023 and 2030

List of Tables:

  • Table 3.1: Cancer Specific Cell Surface Markers
  • Table 4.1: Cancer Stem Cell Therapies: Development Pipeline
  • Table 7.1: Cancer Stem Cells: Publication Analysis
  • Table 8.1: Cancer Stem Cells: List of Molecules Profiled (Marketed and Phase III)
  • Table 8.2: Erivedge®: Current Status of Development
  • Table 8.3: Odomzo®: Current Status of Development
  • Table 8.4: BL-8040: Current Status of Development
  • Table 8.5: Imetelstat: Current Status of Development
  • Table 8.6: Napabucasin: Current Status of Development
  • Table 8.6: Rova-T: Current Status of Development
  • Table 9.1: Cancer Stem Cells: List of Molecules Profiled (Phase II)
  • Table 9.2: Amcasertib / BBI-503 (Boston Biomedical)
  • Table 9.3: AZD9150 / ISIS-STAT3-2.5Rx (Ionis Pharmaceuticals / AstraZeneca)
  • Table 9.4: BHQ 880 (MorphoSys / Novartis)
  • Table 9.5: CRLX 101 (Bluelink Pharma)
  • Table 9.6: CX-02 (Cantex Pharmaceuticals)
  • Table 9.7: Glasdegib / PF-04449913 (Pfizer)
  • Table 9.8: GLG-801 (Genus Oncology)
  • Table 9.9: GO-203 (GLG Pharma)
  • Table 9.10: Ibrutinib (Janssen)
  • Table 9.11: MDNA55 (Medicenna Therapeutics)
  • Table 9.12: ONC201 (Oncoceutics)
  • Table 9.13: Patidegib / IPI-926 / Saridegib (PellePharm)
  • Table 9.14: PT2385 (Peloton Therapeutics)
  • Table 9.15: Reparixin (Dompé Farmaceutici)
  • Table 9.16: Sulforadex / SFX-01 (Evgen Pharma)
  • Table 9.17: SUBA-Itraconazole (HedgePath Pharmaceuticals)
  • Table 9.18: VicOryx (ORYX)
  • Table 10.1: Cancer Stem Cell Therapies: Expected Launch Years of Advanced Stage Drug Candidates
  • Table 10.2: Erivedge®: Target Patient Population
  • Table 10.3: Odomzo®: Target Patient Population
  • Table 10.4: Napabucasin: Target Patient Population
  • Table 10.5: BL-8040: Target Patient Population
  • Table 10.6: Rova-T: Target Patient Population
  • Table 10.7: Imetelstat: Target Patient Population
  • Table 10.8: BHQ 880: Target Patient Population
  • Table 10.9: CRLX101: Target Patient Population
  • Table 10.10: Glasdegib: Target Patient Population
  • Table 10.11: Amcasertib: Target Patient Population
  • Table 10.12: CX-02: Target Patient Population
  • Table 10.13: GLG-801: Target Patient Population
  • Table 10.14: MDNA55: Target Patient Population
  • Table 10.15: ONC201: Target Patient Population
  • Table 10.16: Patidegib: Target Patient Population
  • Table 10.17: Reparixin: Target Patient Population
  • Table 10.18: SUBA-Itraconazole: Target Patient Population
  • Table 10.19: VicOryx: Target Patient Population
  • Table 10.20: SFX-01: Target Patient Population
  • Table 10.21: Ibrutinib: Target Patient Population
  • Table 10.22: PT2385: Target Patient Population
  • Table 10.23: GO-203: Target Patient Population
  • Table 10.24: AZD9150: Target Patient Population
  • Table 13.1: Global Cancer Incidence in 2016: Distribution by Type of Cancer
  • Table 13.2: Cancer Stem Cell Therapies: Distribution by Phase of Development
  • Table 13.3: Cancer Stem Cell Therapies: Distribution by Therapeutic Area
  • Table 13.4: Cancer Stem Cell Therapies: Distribution by Therapeutic Strategies
  • Table 13.5: Cancer Stem Cell Therapies: Distribution by Therapeutic Strategies and Phase of Development
  • Table 13.6: Cancer Stem Cell Therapies: Distribution by Type of Molecule
  • Table 13.7: Cancer Stem Cell Therapies: Route of Administration
  • Table 13.8: Cancer Stem Cell Therapies: Distribution by Geography of Developer
  • Table 13.9: Cancer Stem Cell Therapies: Most Active Industry Players
  • Table 13.10: Cancer Stem Cells: Year-wise Trend by Number of Tweets (2012-2017)
  • Table 13.11: Cancer Stem Cells: Year-Wise Trend of Number of Publications (2008-2016)
  • Table 13.12: Cancer Stem Cells Publication Analysis: Key Journals
  • Table 13.13: Erivedge®: Annual Sales, 2013-2016 (CHF Million)
  • Table 13.14: Roche: Annual Revenues, 2012-H1 2017 (CHF Billion)
  • Table 13.15: Novartis: Annual Revenues, 2011-H1 2017 (USD Billion)
  • Table 13.16: Geron: Annual Revenues, 2012-H1 2017 (USD Million)
  • Table 13.17: Sumitomo Dainippon Pharma: Annual Revenues, 2012-2016 (JPY Billion)
  • Table 13.18: AbbVie: Annual Revenues, 2012-H1 2017 (USD Billion)
  • Table 13.19: Overall Cancer Stem Cell Therapies Market (Till 2030): Base Scenario (USD Billion)
  • Table 13.20: Overall Cancer Stem Cell Therapies Market (Till 2030): Optimistic Scenario (USD Billion)
  • Table 13.21: Overall Cancer Stem Cell Therapies Market (Till 2030): Conservative Scenario (USD Billion)
  • Table 13.22: Cancer Stem Cell Therapies Market: Distribution by Indication, 2017-2030 (USD Billion)
  • Table 13.23: Cancer Stem Cell Therapies Market: Distribution by Therapeutic Target, 2017-2030 (USD Billion)
  • Table 13.24: Cancer Stem Cell Therapies Market: Distribution by Type of Molecule, 2017-2030 (USD Billion)
  • Table 13.25: Cancer Stem Cell Therapies Market: Leading Drug Candidates, 2017, 2024, 2030 (USD Billion)
  • Table 13.26: Erivedge® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.27: Erivedge® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.28: Erivedge® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.29: Odomzo® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.30: Odomzo® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.31: Odomzo® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.32: Napabucasin Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.33: Napabucasin Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.34: Napabucasin Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.35: BL-8040 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.36: BL-8040 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.37: BL-8040 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.38: Rova-T Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.39: Rova-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.40: Rova-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.41: Imetelstat Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.42: Imetelstat Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.43: Imetelstat Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.44: BHQ 880 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.45: BHQ 880 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.46: BHQ 880 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.47: CRLX101 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.48: CRLX101 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.49: CRLX101 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.50: Glasdegib Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.51: Glasdegib Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.52: Glasdegib Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.53: Amcasertib Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.54: Amcasertib Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.55: Amcasertib Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.56: CX-02 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.57: CX-02 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.58: CX-02 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.59: GLG-801 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.60: GLG-801 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.61: GLG-801 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.62: MDNA55 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.63: MDNA55 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.64: MDNA55 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.65: ONC201 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.66: ONC201 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.67: ONC201 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.68: Patidegib Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.69: Patidegib Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.70: Patidegib Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.71: Reparixin Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.72: Reparixin Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.73: Reparixin Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.74: SUBA-Itraconazole Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.75: SUBA-Itraconazole Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.76: SUBA-Itraconazole Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.77: VicOryx Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.78: VicOryx Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.79: VicOryx Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.80: SFX-01 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.81: SFX-01 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.82: SFX-01 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.83: Ibrutinib Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.84: Ibrutinib Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.85: Ibrutinib Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.86: PT2385 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.87: PT2385 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.88: PT2385 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.89: GO-203 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.90: GO-203 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.91: GO-203 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 13.92: AZD9150 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 13.93: AZD9150 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 13.94: AZD9150 Sales Forecast (Till 2030): Conservative Scenario (USD Million)

Company Listed:

The following companies and organizations have been mentioned in the report:

  • 1. 4SC
  • 2. Abbott Laboratories
  • 3. AbbVie
  • 4. Admune Therapeutics
  • 5. Advanced Accelerator Applications
  • 6. Agalimmune
  • 7. Agilvax
  • 8. Alcon
  • 9. Almac Discovery
  • 10. amcure
  • 11. Anadys Pharmaceuticals
  • 12. AndroScience Corporation
  • 13. Apexian Pharmaceuticals
  • 14. Aptose Biosciences
  • 15. ASINEX
  • 16. AstraZeneca
  • 17. BeiGene
  • 18. BetaCat Pharmaceuticals
  • 19. Beth Israel Deaconess Medical Center
  • 20. BioLineRx
  • 21. BioImagene
  • 22. Biokine Therapeutics
  • 23. Bionomics
  • 24. BlueLink Pharmaceuticals
  • 25. Bristol-Myers Squibb (BMS)
  • 26. Boehringer Ingelheim
  • 27. Boston Biomedical
  • 28. BridgeBio Pharma
  • 29. Cancer Therapy and Research Center
  • 30. Cantargia
  • 31. Cantex Pharmaceuticals
  • 32. Canvax Biotech
  • 33. Carna Biosciences
  • 34. Celgene
  • 35. CellCentric
  • 36. Cellerant Therapeutics
  • 37. Cellestia Biotech
  • 38. Celon Pharma
  • 39. Centre Léon Bérard
  • 40. Cerulean Pharma
  • 41. Chugai Pharmaceutical
  • 42. Ciba-Geigy
  • 43. Circle Pharma
  • 44. Cleveland Clinic
  • 45. Constellation Pharmaceuticals
  • 46. Cormorant Pharmaceuticals
  • 47. Curegenix
  • 48. Curis
  • 49. CytomX Therapeutics
  • 50. D3 (Drug Discovery and Development)
  • 51. Dana-Farber Cancer Institute
  • 52. Dompé Farmaceutici
  • 53. Duke University Medical Center
  • 54. Eli Lilly
  • 55. Encore Vision
  • 56. epiSCI
  • 57. Escend Pharmaceuticals
  • 58. Evgen Pharma
  • 59. Exiris
  • 60. Foresite Capital Management
  • 61. Fox Chase Cancer Center
  • 62. Genentech
  • 63. Genoscience Pharma
  • 64. Genus Oncology
  • 65. Geron
  • 66. Glactone Pharma
  • 67. GLG Pharma
  • 68. GliGene
  • 69. GlycArt Biotechnology
  • 70. GlycoMimetics
  • 71. Glaxo Smith Kline (GSK)
  • 72. HedgePath Pharmaceuticals
  • 73. HitGen
  • 74. iβeCa Therapeutics
  • 75. Ignyta
  • 76. ImmunoCellular Therapeutics
  • 77. ImmuVen
  • 78. IMPACT Therapeutics
  • 79. inVentiv Health Clinical
  • 80. Ionis Pharmaceuticals
  • 81. Janssen
  • 82. JCR Pharmaceuticals
  • 83. JW Pharmaceutical
  • 84. Kancera
  • 85. KYORIN Pharmaceutical
  • 86. Kyoto University
  • 87. Leap Therapeutics
  • 88. Lynx Therapeutics
  • 89. Maastricht University Medical Center
  • 90. MacroGenics
  • 91. Manchester Cancer Research Centre
  • 92. Marina Biotech
  • 93. Massachusetts General Hospital
  • 94. MAX BioPharma
  • 95. Mayne Pharma
  • 96. MD Anderson Cancer Center
  • 97. MecRx
  • 98. Medicenna Therapeutics
  • 99. Merck
  • 100. METABOSTEM
  • 101. MolMed
  • 102. MorphoSys
  • 103. Mosaic Biomedicals
  • 104. National Cancer Institute (NCI)
  • 105. National Institute of Neurological Disorders and Stroke (NINDS)
  • 106. National OncoVenture
  • 107. NewLink Genetics
  • 108. Nexigen
  • 109. Nextech Invest
  • 110. Northern Biologics
  • 111. Novartis
  • 112. Omeros
  • 113. Oncoceutics
  • 114. OncoImmune
  • 115. OncoMed Pharmaceuticals
  • 116. OncoTherapy Science
  • 117. OncoViRx
  • 118. Oncternal Therapeutics
  • 119. ORYX
  • 120. OxStem
  • 121. PellePharm
  • 122. Peloton Therapeutics
  • 123. Peptomyc
  • 124. Pfizer
  • 125. PharmAbcine
  • 126. Pharmacyclics
  • 127. PRISM Pharma
  • 128. Proximagen
  • 129. PTC Therapeutics
  • 130. Redx Pharma
  • 131. Regen BioPharma
  • 132. Remeditex
  • 133. RhemaStem
  • 134. Roche
  • 135. Samumed
  • 136. Sandoz
  • 137. Sanofi
  • 138. SATHGEN BIOTECH
  • 139. SatRx
  • 140. SciQuus Oncology
  • 141. Selexys Pharmaceuticals
  • 142. Shine Bright Foundation
  • 143. SignalRx
  • 144. Spinifex Pharmaceuticals
  • 145. Splash Pharmaceuticals
  • 146. Stemcentrx
  • 147. Stemline Therapeutics
  • 148. StemMed
  • 149. StemSynergy Therapeutics
  • 150. Sumitomo Dainippon Pharma
  • 151. Sumo Biosciences
  • 152. Sun Pharmaceutical
  • 153. SupremeCure Pharma
  • 154. Surrozen
  • 155. Syntex
  • 156. Taiwan Liposome Company
  • 157. TargaGenix
  • 158. Tensha Therapeutics
  • 159. TESARO
  • 160. The Column Group
  • 161. The Wistar Institute
  • 162. The Royal Marsden NHS Foundation Trust
  • 163. Tichenor Ventures
  • 164. Tolero Pharmaceuticals
  • 165. Topspin Partners
  • 166. University of Pittsburgh
  • 167. Venn Therapeutics
  • 168. Ventana Medical Systems
  • 169. Verastem
  • 170. WntResearch
  • 171. Ziarco Group
Back to Top